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The epithelial-to-mesenchymal transition (EMT) transcriptional program is characterized by repression of 
E-cadherin (CDH1) and induction of N-cadherin (CDH2), and mesenchymal genes like vimentin (VIM). Pla-
centa-specific 8 (PLAC8) has been implicated in colon cancer; however, how PLAC8 contributes to disease is 
unknown, and endogenous PLAC8 protein has not been studied. We analyzed zebrafish and human tissues and 
found that endogenous PLAC8 localizes to the apical domain of differentiated intestinal epithelium. Colon 
cancer cells with elevated PLAC8 levels exhibited EMT features, including increased expression of VIM and 
zinc finger E-box binding homeobox 1 (ZEB1), aberrant cell motility, and increased invasiveness. In contrast to 
classical EMT, PLAC8 overexpression reduced cell surface CDH1 and upregulated P-cadherin (CDH3) without 
affecting CDH2 expression. PLAC8-induced EMT was linked to increased phosphorylated ERK2 (p-ERK2), and 
ERK2 knockdown restored cell surface CDH1 and suppressed CDH3, VIM, and ZEB1 upregulation. In vitro, 
PLAC8 directly bound and inactivated the ERK2 phosphatase DUSP6, thereby increasing p-ERK2. In a murine 
xenograft model, knockdown of endogenous PLAC8 in colon cancer cells resulted in smaller tumors, reduced 
local invasion, and decreased p-ERK2. Using MultiOmyx, a multiplex immunofluorescence-based methodol-
ogy, we observed coexpression of cytosolic PLAC8, CDH3, and VIM at the leading edge of a human colorectal 
tumor, supporting a role for PLAC8 in cancer invasion in vivo.
Introduction
Placenta-specific 8 (PLAC8), previously called Onzin, is a 115–
amino acid, cysteine-rich protein first identified in human den-
dritic cells (1). By in situ hybridization (ISH), Plac8 expression is 
highly expressed in giant trophoblasts and the spongiotrophoblast 
layer in mouse placenta (2). Subsequently, Plac8 mRNA expression 
was observed in myeloid and lymphoid cells, as well as in epithelial 
cells in the lung and intestine (3). Plac8-deficient mice have defects 
in innate immunity (3) and exhibit contact hypersensitivity (4), 
impaired brown and white fat differentiation, and late-onset obe-
sity (5, 6). In addition, Plac8 transcripts are upregulated in immor-
talized mouse colonocytes transformed by combined mutant H-ras 
and p53 (7). Knockdown of endogenous Plac8 in these cells and in a 
human colorectal cancer (CRC) cell line, HT-29, reduces growth of 
xenografts in nude mice (7). Although PLAC8 has important roles 
in normal physiology, and a possible role in CRC, its molecular 
function(s) and the cellular distribution of endogenous protein 
have not been studied.
Epithelial-to-mesenchymal transition (EMT) is a complex devel-
opmental process that drives key morphogenetic events, such as 
gastrulation and neural crest migration. During the process of 
EMT, cohesive epithelial cells undergo a loss of apicobasal polarity 
and cell-cell contact, while acquiring mesenchymal characteristics, 
enabling them to move as individual cells (8–11). EMT is thought 
to be a transcriptional program involving repression of CDH1 and 
concomitant induction of CDH2 and mesenchymal genes like VIM 
(12–14). In carcinoma, there appears to be inappropriate activa-
tion of the EMT program, whereby tumor cells become mesenchy-
mal-like, enabling them to delaminate from the primary tumor 
and invade locally (15–18).
Herein, by combined analysis of zebrafish and human tissues, 
we show that PLAC8 protein is present in normal intestine, where 
it localizes to the apical domain of differentiated intestinal epi-
thelium. However, PLAC8 is upregulated and cytosolic in med-
ullary and mucinous CRC, and cytosolic PLAC8 correlates with 
tumor progression and tumor grade. Overexpression of PLAC8 in 
a human CRC cell line, HCA-7, results in morphological, molecu-
lar, and functional features of EMT. Unlike in classical EMT, there 
is post-transcriptional reduction in cell surface CDH1 and no 
change in CDH2; however, there is a cadherin switch with tran-
scriptional upregulation of CDH3, a cadherin previously linked to 
colon cancer progression (19–21). PLAC8-overexpressing HCA-7 
cells exhibit elevated levels of phosphorylated ERK2 (p-ERK2), 
previously shown to induce EMT (22). We show that PLAC8 selec-
tively binds and inhibits the enzymatic activity of dual-specific-
ity phosphatase 6 (DUSP6), an ERK2 phosphatase (23), thereby 
increasing p-ERK2 and leading to an unconventional EMT.
Results
Endogenous PLAC8 protein localizes to the apical domain of terminally 
differentiated human colonic epithelium. Plac8 expression increases in 
immortalized mouse colonocytes transformed by mutant H-ras 
and p53, and Plac8 knockdown reduces tumor growth in xeno-
grafts (7). However, how PLAC8 contributes to colonic neoplasia 
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is unknown. To address the role of PLAC8 in CRC, we examined 
its distribution in both normal and neoplastic human colon 
by immunofluorescence using a commercial PLAC8-specific 
polyclonal antibody. PLAC8 was found exclusively at the apical 
domain of fully differentiated normal colonic epithelium in both 
colonocytes (Figure 1, A and B) and goblet cells (Supplemental 
Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI71103DS1). We observed abrupt loss 
of PLAC8 immunoreactivity in epithelial cells deeper in the crypt 
(Figure 1, A and B) and absence of PLAC8 staining at the crypt base 
(Supplemental Figure 1, C and D). Staining was also observed in 
some scattered mononuclear cells in the stroma (A. Powell and R. 
Coffey, unpublished observations).
Cytosolic PLAC8 is correlated with tumor grade and linked to medul-
lary and mucinous CRC. We next analyzed PLAC8 expression in CRC 
using a tissue microarray (TMA) that contains a broad representa-
tion of stages and subtypes (24). In 49% of cases (41/84), no stain-
ing was observed in the malignant epithelium (Supplemental Fig-
ure 1F), while the remaining 51% (43/84) displayed membranous 
and/or cytosolic PLAC8 staining in the cancer. In cases where epi-
thelial expression of PLAC8 was lost, stromal expression was still 
observed (C. Li and R. Coffey, unpublished observations), indicat-
ing that the lack of PLAC8 signal in the epithelium was not due to 
sample quality. In moderately differentiated colorectal adenocar-
cinomas, PLAC8 localized to the apical domain, similar to its dis-
tribution in normal colon (Figure 1C), although staining extended 
deeper into neoplastic crypts (Figure 1D and Supplemental Fig-
ure 1E). PLAC8 staining was confined to the cytoplasm in 9 cases 
(11%), where it correlated with higher tumor grade (P = 0.0009) 
(Supplemental Table 1). Notably, cases with strong cytosolic 
PLAC8 expression fall into 2 histological subtypes: medullary (Fig-
ure 1, E and F) and mucinous (Figure 1, G and H) carcinomas. As 
expected, CDH1 was present along the basolateral membrane of 
polarized normal and most neoplastic epithelia (Figure 1, A, B, and 
D, and Supplemental Figure 1). In areas with prominent PLAC8 
immunofluorescence, CDH1 was less membranous.
PLAC8 overexpression increases tumor cell growth and invasion. We 
generated a polyclonal rabbit anti-PLAC8 antibody, validated its 
specificity for immunoblotting (Supplemental Figure 2), and used 
it to examine a battery of human CRC cell lines cultured on plas-
tic. In 2 matched primary and metastatic CRC cell lines, PLAC8 
levels were higher in the metastatic cells compared with primary 
cell lines: SW620 versus SW480 (25) and KM12SM versus KM12C 
(ref. 26 and Figure 2A). The strongest PLAC8 signal was found in 
LoVo cells, a microsatellite unstable mucinous cell line (27). In 2 
HCA-7 subclones, CC and SC (described below), PLAC8 levels were 
higher in SC than parental HCA-7 cells, whereas PLAC8 was not 
detected in CC (Figure 2A).
We cultured HCA-7 cells in type I collagen and identified 2 types 
of colonies with distinct morphologies (Figure 2B) and markedly 
different levels of PLAC8 (Figure 2, A and C): hollow cysts lined by 
a single layer of polarized cells enclosing a central lumen (designat-
ed cystic clones, CC) with undetectable levels of PLAC8, and solid 
masses with ill-defined borders and protrusions (designated spiky 
clones, SC) with high levels of PLAC8. When CC and SC cells were 
injected subcutaneously into athymic nude mice, they retained 
their in vitro morphologies: CC cells formed well-differentiated, 
encapsulated cysts, whereas SC cells formed poorly differentiated 
tumors that invaded into adjacent skeletal muscle (Figure 2B). By 
immunofluorescence, PLAC8 was not detected in CC tumors but 
was present and largely cytosolic in SC tumors (Figure 2B). More-
over, knockdown of endogenous PLAC8 in SC cells resulted in 
reduced growth in both type I collagen and xenografts (Figure 2C, 
Figure 1
PLAC8 immunofluorescence in normal and neoplastic human colon. 
(A and B) In normal colon, PLAC8 immunofluorescence (red) local-
izes to the apical domain of the differentiated colonic epithelium at the 
top of crypts. The boxed region in A is magnified in B. Epithelial cells 
are outlined by CDH1 immunofluorescence (green). (D) In a typical 
moderately differentiated adenocarcinoma (H&E-stained sections at 
lower magnification are shown in C), PLAC8 also localizes to the api-
cal domain, but immunoreactivity extends deeper into the neoplastic 
crypts. (F and H) PLAC8 immunofluorescence is largely detected in the 
cytoplasm of medullary (F) and mucinous (H) adenocarcinoma. (C, E, 
and G) Serial H&E-stained sections at lower magnification correspond 
to similar areas in D, F, and H. In all immunofluorescent panels, DAPI 
(blue) marks nuclei. Scale bars: 100 μm.
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Figure 2
Increased PLAC8 protein is linked to tumor progression. (A) Immunoblotting of CRC cell lines shows PLAC8 levels are higher in cells 
derived from metastatic tumors (SW620 and KM12SM) compared with cells derived from primary tumors (SW480 and KM12C), as well 
as in more invasive SC cells compared with CC or parental HCA-7 cells. (B) Left: DIC micrographs of 2 distinct types of HCA-7 colonies in 
3D collagen culture: cystic clones (CC) that form smooth-edged spheres and spiky clones (SC) that grow as a solid mass with ill-defined 
borders and multiple protrusions (left panel) and phalloidin staining (right panel). Right: H&E staining of subcutaneous xenograft tumors 
of CC and SC cells (left panels); PLAC8 immunofluorescence of CC and SC subcutaneous xenograft tumors (right panels). (C) In 3D col-
lagen culture, by immunoblotting, PLAC8 was undetectable in CC cells, but highly expressed in SC cells, and could be efficiently knocked 
down by 2 shRNAs in SC cells (left panel). PLAC8 knockdown in SC cells significantly decreased colony number in 3D collagen culture, 
and reduced tumor volume in xenografts (right panel; **P < 0.01). (D) Knockdown of endogenous PLAC8 in the KM12SM CRC cell line 
significantly reduced tumor volume of xenografts (left graph, *P < 0.05, n = 7). Right panels are representative H&E-stained tissue sections 
of xenografts. Data in all graphs are presented as mean ± SEM. Scale bars: 100 μm.
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right panels). In addition, knockdown of endogenous PLAC8 in 
KM12SM cells (Figure 2D, left panel) and LoVo cells (Supplemen-
tal Figure 3) reduced tumor growth in nude mice. There appeared 
to be reduced local invasion into skeletal muscle in xenografts of 
KM12SM cells with PLAC8 knockdown compared with vector con-
trol (Figure 2D, right panels). Taken together, these studies sug-
gest PLAC8 overexpression may contribute to CRC progression.
Identification and characterization of zebrafish plac8 homologs. To eluci-
date the cellular and molecular functions of PLAC8 in vivo, we took 
advantage of the experimental tractability afforded by the zebrafish 
model (28). Using the reciprocal best hits method (29), we identified 
the zebrafish Zgc114201 gene that encodes a cysteine-rich protein 
with 44% amino acid identity (including 13 of 16 cysteines) and 62% 
similarity to human PLAC8 (Supplemental Figure 4, A and C). In phy-
logenetic analyses, this putative zebrafish Plac8 clustered with Plac8 
proteins from other species (Supplemental Figure 4E). Importantly, 
analysis of the human, mouse, and zebrafish genomes revealed that 
Zgc114201 is a syntenic equivalent of human PLAC8 (Supplemental 
Figure 4B). We noted that the second best hit, Zgc158845 (42% identity, 
56% similarity to PLAC8), was located next to Zgc114201 (Supplemen-
tal Figure 4, B and C). Given their physical proximity and structural 
similarity, Zgc114201 and Zgc158845 likely arose via a tandem gene 
duplication event (30). According to the zebrafish gene nomenclature 
guidelines, we designated these genes plac8.1 and plac8.2, respectively. 
Using RT-PCR, we found that plac8.1 was prominently expressed in 
multiple developmental stages, whereas plac8.2 was expressed at low 
levels during early embryogenesis (Supplemental Figure 4D). Thus, 
we elected to focus on plac8.1 in this study.
Whole-mount ISH revealed that plac8.1 RNA was expressed mater-
nally and zygotically in a ubiquitous fashion (Figure 3A) until 4 
days post-fertilization (dpf), when it was upregulated in the gut and 
downregulated in other tissues (Figure 3C). To investigate Plac8.1 
protein distribution, we generated a rabbit polyclonal antibody 
against a C-terminal peptide and validated its specificity by immu-
noblotting (Supplemental Figure 2, C and D). Using this antibody, 
we found widespread Plac8.1 immunofluorescence during gastrula-
tion stages (Figure 3B, left panels). Strikingly, the intracellular distri-
bution of Plac8.1 in mesenchymal gastrula cells was largely cytosolic 
at the onset of gastrulation but became progressively enriched at 
the plasma membrane at later gastrula stages (Figure 3B), during 
which cells begin to manifest epithelial characteristics (31, 32). This 
dynamic pattern of intracellular distribution was also observed in 
gastrulae expressing a C-terminal fusion protein, Plac8.1-EGFP 
(Figure 4B) or Plac8.1-HA (H. Ma, L. Solnica-Krezel, and R. Coffey, 
unpublished observations). Given the accumulation of plac8.1 tran-
scripts in the gut, we next analyzed its distribution in this organ. As 
in the human intestine, Plac8.1 was enriched at the apical surface of 
gut epithelial cells at 4 dpf (Figure 3D). Thus, Plac8.1 intracellular 
distribution is dynamic and highly regulated in a developmental 
stage– and cell type–dependent manner.
Figure 3
plac8.1 RNA expression and Plac8.1 protein localization in zebrafish embryos. (A) Whole-mount ISH using an antisense probe against full-length 
plac8.1 in zebrafish embryos at indicated hours post-fertilization (hpf). Asterisks denote position of animal poles. The arrow and arrowhead denote 
future dorsal and ventral side, respectively. Scale bar: 200 μm. (B) Confocal immunofluorescent images of whole-mount zebrafish embryos 
stained with anti-Plac8.1 antibody (green) and Texas red–conjugated phalloidin (red, F-actin). Cartoons on the left of each panel illustrate cor-
responding stages. The dashed lines correspond to their right section planes. Scale bar: 10 μm. (C) Whole-mount ISH using plac8.1 antisense 
probe in zebrafish embryos at 4 days post-fertilization (dpf). Dashed line indicates approximate position for transverse section shown in inset with 
strong signal in gut. Scale bars: 250 μm. (D) Cryosections through the gut of embryos at 4 dpf were stained with anti-Plac8.1 antibody (green), 
Texas red–conjugated phalloidin (red, F-actin), and TO-PRO-3 (blue, DNA). Scale bar: 10 μm.
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Figure 4
Plac8.1 overexpression causes cell-autonomous post-transcriptional downregulation of E-cadherin. (A) Left: Representative micrographs of 
control or plac8.1 RNA–injected zebrafish embryo. Horizontal white lines mark the deep cell margin. Middle: ntl ISH. The vertical white lines 
denote midline tissues, and the red arrowhead indicates the cluster of dorsal forerunner (df) cells separated from the deep cell margin. Right: 
Micrographs of control and plac8.1 RNA–injected embryos at 3 days post-fertilization (dpf), with ventral view of eyes shown in insets. Scale 
bars: 200 μm (7.5 hpf); 500 μm (3 dpf); 100 μm (insets). (B) Representative micrographs of a cell cluster with 3 types of membrane junctions: 
those shared by 2 wild-type cells (white arrows); those shared by 2 Plac8.1-EGFP–overexpressing cells (cyan arrow); and hybrid membrane 
junctions (green arrows). Scale bars: 10 μm. (C) Quantification of membrane Cdh1 intensity at different membrane junctions. **P < 0.01, 
ANOVA and subsequent pair-wise t test. (D and E) Quantification of total speed and net speed of lateral mesodermal cells. **P < 0.01, t test. 
(F) Left: Representative paths of lateral mesodermal cells traveling during time lapse in control and Plac8.1-EGFP–overexpressing embryos. 
Right: Orientations of the long axes of lateral mesodermal cells are plotted with length/width ratio (LWR) expressed as mean ± SEM. 
P > 0.05, Mann-Whitney U test. (G) qRT-PCR of cdh1 expression in Plac8.1-overexpressing and control embryos. Data are presented as 
mean ± SEM (P > 0.05, t test). (H) Immunoblotting of Cdh1 levels in control and Plac8.1-overexpressing embryos at 50% epiboly. Normalized 
levels are shown as mean ± SEM (P < 0.01, t test).
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Overexpression of Plac8.1 impairs gastrulation, phenocopying Cdh1 loss-of-
function. To gain mechanistic insight into the effects of Plac8.1 over-
expression, we injected various amounts of synthetic plac8.1 RNA 
into 1-cell-stage zebrafish embryos (Figure 4A). Plac8.1-overexpress-
ing embryos displayed normal morphology until gastrulation, when 
cells accumulated predominantly in the dorsal region of the gastru-
la (Figure 4A). Moreover, the blastoderm margin was further away 
from the vegetal pole in Plac8.1-overexpressing embryos compared 
with control embryos (uninjected or EGFP RNA–injected wild-type). 
These results indicate that excess Plac8.1 impairs epibolic move-
ments that spread embryonic tissues around the yolk. Accordingly, 
expression of the mesodermal marker no tail (ntl, zebrafish brachy-
ury homolog) (33) at the blastoderm margin was positioned further 
from the vegetal pole in embryos overexpressing Plac8.1 compared 
with control embryos. Moreover, the ntl expression domain, mark-
ing dorsal forerunner cells (normally in close contact with the dor-
sal blastoderm margin), was separated from the deep cell margin in 
embryos overexpressing Plac8.1 (Figure 4A, red arrowhead), a phe-
notype consistent with defective epiboly (34). In addition, the ntl 
expression domain in the nascent chordamesoderm was shortened 
anteroposteriorly, but broadened mediolaterally (Figure 4A, white 
lines of middle panels), suggesting that excess Plac8.1 also impairs 
convergence and extension gastrulation movements.
At the completion of embryogenesis, Plac8.1-overexpressing 
embryos manifested dorsally curved and shortened body axes, 
with a small fraction displaying various degrees of cyclopia (Fig-
ure 4A, right panels). Injection of exogenous RNA encoding 
human PLAC8 led to a similar phenotype (H. Ma, L. Solnica-
Krezel, and R. Coffey, unpublished observations). Penetrance of 
the defective gastrulation phenotypes described above increased 
in a concentration-dependent manner (Supplemental Figure 5A) 
and was reduced by coinjection with a plac8.1 antisense morpho-
Figure 5
Expression of PLAC8 enhances HCA-7 cell invasion and alters CDH1 subcellular localization. (A) 2D invasive capacity was assessed by a 
magnetically attachable stencil invasion assay. After removal of a magnetically attachable stencil, movement of parental HCA-7 and PLAC8-
overexpressing HCA-7 (HCA-7P8) cells was monitored over 24 hours by time-lapse microscopy. HCA-7 cells moved as a common front, whereas 
HCA-7P8 cell movement was uneven and cells detached. Scale bars: 100 μm. (B) At 8 and 24 hours, static images were taken and quantified by 2 
parameters (deviation ratio and number of detached cells per field), based on 3 independent experiments performed in triplicate. Both parameters 
were significantly greater in PLAC8-overexpressing cells. Data are presented as mean ± SD. *P < 0.05; **P < 0.01. (C) After 15 days in 3D collagen 
culture, PLAC8 and CDH1 immunofluorescence were largely cytosolic in HCA-7 cells overexpressing PLAC8 (HCA-7P8). The boxed regions in 
the upper panels are magnified in the lower panels. Scale bars: 50 μm.
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Figure 6
HCA-7P8 cells exhibit features of EMT. (A) qRT-PCR demonstrated that CDH1 was slightly upregulated, 1.4-fold, whereas ZEB1, VIM, and 
CDH3 were markedly upregulated, 13-, 5-, and 4-fold, respectively, in HCA-7P8 cells compared with HCA-7 cells. OCLN and AKT expression 
was not significantly changed. Data are presented as mean ± SD. (B) By detergent fractionation analysis, most CDH1 in HCA-7P8 cells was in 
the Triton X-100 soluble fraction. Control HCA-7 cells had approximately 50% insoluble CDH1, reflecting cytoskeleton-attached CDH1. CDH3 
in HCA-7P8 cells was predominantly Triton X-100 soluble. ACTB and AKT serve as fractionation controls. (C) Expression and localization of 
classical EMT markers were assessed by immunoblotting (left) and immunofluorescence (right). In contrast to RNA levels, CDH1 protein was 
modestly reduced in HCA-7P8 cells and appeared less membranous and more cytoplasmic. CTNND1 was slightly reduced in HCA-7P8 cells; 
consistent with qRT-PCR results, VIM, ZEB1, and CDH3 protein levels were upregulated. In HCA-7P8 cells, VIM immunofluorescence was 
observed in approximately 10% of the cells, where it had a cytoplasmic filamentous pattern. ZEB1 fluorescence was uniformly nuclear, and 
CDH3 appeared more cytoplasmic compared with that in HCA-7 cells. (D) Expression and localization of tight junction proteins were assessed 
by immunoblotting (left) and immunofluorescence (right). Compared with HCA-7 cells, there was no change in total OCLN protein levels in 
HCA-7P8 cells; however, there was a marked reduction in membrane localization, with appearance of punctate cytoplasmic immunoreactivity. 
TRIC and CLDN4 protein levels were upregulated with loss of tricellular junction localization. Scale bars: 20 μm.
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lino oligonucleotide, MO1-plac8.1, which inhibits translation of 
the injected plac8.1 RNA (H. Ma, L. Solnica-Krezel, and R. Coffey, 
unpublished observations). Taken together, these data indicate 
that the observed defects in epiboly and convergence and exten-
sion gastrulation movements are due to overexpression of Plac8.1.
To determine the cellular basis of these gastrulation abnormali-
ties, we compared the movements of lateral mesodermal cells in 
control embryos and embryos overexpressing Plac8.1-EGFP using 
Nomarski time-lapse analysis. Cells from control and Plac8.1-
EGFP–overexpressing embryos showed similar length/width 
ratios, suggesting that Plac8.1 overexpression does not affect cell 
elongation (Figure 4F, right panels). Also, the orientation of cell 
bodies in Plac8.1-EGFP–overexpressing gastrulae showed a pattern 
similar to that in controls (Figure 4F, right panels). 
Tracking the positions of representative mesodermal 
cells over time revealed normal cell migration paths in 
Plac8.1-EGFP–overexpressing gastrulae (Figure 4F, left 
panels). However, both the total and net cell migration 
speeds were significantly reduced in embryos overex-
pressing Plac8.1-EGFP compared with control gastru-
lae (Figure 4, D and E).
Plac8.1 overexpression causes cell-autonomous, post-
transcriptional downregulation of cdh1. The morphoge-
netic phenotypes observed in gastrulae overexpressing 
Plac8.1 resembled cdh1 loss-of-function phenotypes 
(34–38). If Plac8.1 influences Cdh1 function dur-
ing gastrulation, embryos with reduced Cdh1 levels 
should be sensitive to Plac8.1 expression levels. To test 
this, we injected a low dose of plac8.1 RNA (20 pg) into 
offspring of cdh1vu44/+ parents and monitored epiboly 
progression using ntl as a marker of the blastoderm 
margin. The resulting progeny were characterized into 
3 distinct phenotypes: wild-type gastrulae had a very 
mild epiboly defect; cdh1vu44/+ heterozygotes manifested 
more severe epiboly defects (Supplemental Figure 5B, 
lower right panel); and cdh1vu44/vu44 homozygotes dis-
played the most severe phenotype (H. Ma, L. Solnica-
Krezel, and R. Coffey, unpublished observations). This 
synergistic epiboly defect in cdh1vu44/+ heterozygous 
embryos expressing low amounts of Plac8.1 supports the notion 
that Plac8.1 negatively influences cdh1 gene expression or function.
We next examined whether Plac8.1 affected cdh1 transcript levels. 
By quantitative RT-PCR (qRT-PCR), cdh1 mRNA levels were not 
significantly different between uninjected control and Plac8.1-
overexpressing embryos (Figure 4G), suggesting that Plac8.1 
represses cdh1 post-transcriptionally. In fact, Cdh1 protein levels 
were reduced by about 50% in embryos overexpressing Plac8.1 
compared with controls (Figure 4H). To test whether Plac8.1 
regulated Cdh1 levels in a cell-autonomous manner, we injected 
plac8.1-EGFP RNA into 1 cell of 32-cell-stage embryos, and moni-
tored Cdh1 by immunofluorescence at early gastrula stages (Fig-
ure 4B). Cdh1 membrane immunofluorescence was significantly 
Figure 7
PLAC8 induces EMT through ERK2 activation. (A) Total 
and activated EMT-related kinases were assessed by 
immunoblotting. Although both p-ERK1 (slower migrating, 
higher band) and p-ERK2 (faster migrating, lower band) 
were increased in HCA-7P8 cells, ERK2 phosphorylation 
was much stronger. Total ERK1/2 proteins were expressed 
at similar levels in HCA-7 and HCA-7P8 cells. Total AKT 
and p-AKT were slightly increased, whereas total SRC and 
p-SRC (Y416) were unchanged in PLAC8-overexpressing 
HCA-7 cells. (B) Immunoblotting of HCA-7P8 cells infected 
with nontargeting shRNA vector control (CTL), or shRNAs 
targeting ERK1 or ERK2, respectively. (C) Representative 
DIC images from shERK1 and shERK2 cells grown on 
coverslips for 5 days showed that knockdown of ERK2, but 
not ERK1, resulted in reversion to smooth-edged colonies 
similar to parental HCA-7 cells. Scale bar: 500 μm. (D) Rep-
resentative immunofluorescent images from shERK1 and 
shERK2 cells showed that knockdown of ERK2, but not 
ERK1, led to restoration of cell surface CDH1 and markedly 
reduced CDH3, VIM, and ZEB1. Scale bars: 50 μm.
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reduced at membranes shared by 2 Plac8.1-overexpressing cells; 
less reduced, yet still significantly reduced, intensity was observed 
at membranes shared by 1 wild-type cell and 1 Plac8.1-EGFP–
expressing cell, compared with Cdh1 levels at membranes shared 
by cells lacking Plac8.1-EGFP (Figure 4C). The Plac8.1-EGFP sig-
nal negatively correlated with Cdh1 signals (Figure 4C; H. Ma, L. 
Solnica-Krezel, and R. Coffey, unpublished observations). Taken 
together, these studies are consistent with a model whereby excess 
Plac8.1 expression negatively regulates Cdh1 levels in zebrafish 
gastrulae post-transcriptionally in a cell-autonomous fashion.
Overexpression of PLAC8 in HCA-7 cells confers an EMT phenotype. 
Armed with the insights gained from studying Plac8.1 in zebrafish, 
we examined the functional consequences of overexpressing PLAC8 
in HCA-7 cells (HCA-7P8). We compared the 2-dimensional (2D) 
invasive behavior of parental and HCA-7P8 cells using a magneti-
cally attachable stencil invasion assay (39). Cells were seeded at high 
density on monomeric collagen, and cell migration was analyzed 
upon removal of a magnetic stencil. Parental HCA-7 cells moved as 
a cohesive sheet, whereas HCA-7P8 cells moved unevenly and tended 
to detach from a common but irregular front (Figure 5A and Sup-
plemental Figure 6). The deviation ratio and number of detached 
cells per field were significantly greater in HCA-7P8 cells than 
those observed in parental HCA-7 cells 8 and 24 hours after stencil 
removal (Figure 5B). When cultured in a 3D collagen matrix, HCA-
7P8 cells showed less membranous CDH1 by immunofluorescence, 
especially cells located at the common front (Figure 5C). A similar 
pattern was observed in SC cells (with high PLAC8 levels) and CC 
cells (with barely detectable PLAC8 levels) cultured in 3D collagen 
(Supplemental Figure 10B). Hence, consistent with our findings 
in zebrafish embryos (Figure 4B), PLAC8 overexpression altered 
HCA-7 cell migration and reduced cell surface expression of CDH1.
Given that PLAC8-overexpressing HCA-7 cells display features 
that are functionally and morphologically similar to EMT, we 
next examined expression of EMT-related genes by using a com-
mercial qRT-PCR array (see Methods; Y. Wang and R. Coffey, 
unpublished observations) and validated individual upregulated 
candidates. Consistent with a classical EMT signature (8), VIM 
and zinc finger E-box binding homeobox 1 (ZEB1) transcripts 
were increased 12- and fourfold, respectively, in HCA-7P8 cells 
compared with parental HCA-7 cells. We were not able to detect 
ZEB2 expression and did not observe changes in other tran-
scriptional regulators of CDH1 (TWIST1 and TWIST2, SNAIL, 
and SLUG) in HCA-7P8 cells (Y. Wang and R. Coffey, unpub-
lished observations). In contrast to transcriptional repres-
sion of CDH1 seen in classical EMT, CDH1 mRNA was slightly 
upregulated (1.4-fold) in HCA-7P8 cells (Figure 6A), and CDH2 
transcripts were undetectable in both cell lines (Y. Wang and R. 
Coffey, unpublished observations). Interestingly, expression of 
CDH3, a cadherin linked to colon cancer progression (20), was 
upregulated nearly fourfold in HCA-7P8 cells. Therefore, PLAC8 
overexpression results in an unconventional cadherin switch: 
transcriptional upregulation of CDH3 and reduced cell surface 
CDH1, along with other typical features of EMT including tran-
scriptional upregulation of VIM and ZEB1.
To determine the post-transcriptional effects of PLAC8 on 
CDH1, we examined the Triton X-100–soluble and –insoluble 
fractions of CDH1 in parental and HCA-7P8 cells. The Triton-
insoluble pool of CDH1 is thought to represent a cytoskeleton-
attached, highly organized complex of functional CDH1 at the 
plasma membrane (40). PLAC8 overexpression reduced the insol-
uble pool of CDH1 (Figure 6B). Thus, like in zebrafish, PLAC8 
overexpression post-transcriptionally regulates CDH1, in this case, 
by reducing the insoluble pool of cytoskeleton-attached CDH1, as 
well as modestly decreasing the total CDH1 protein level (Figure 
6C, left panel). Similar to the changes observed at the transcript 
level, CDH3 protein was increased in HCA-7P8 cells, whereas it 
was barely detected in parental HCA-7 cells. CDH3 was mainly 
detected in the Triton X-100–soluble fraction.
Figure 8
PLAC8 binds to DUSP6 and inhibits its phosphatase activity. (A) PLAC8 inhibited DUSP6 phosphatase activity in vitro. DUSP6 phosphatase activ-
ity was measured by fluorescent intensity of the substrate 3-O-methylfluorescein phosphate. Fluorescent intensity increased over time in control 
samples (black squares). Addition of purified MBP-tagged mouse PLAC8 protein significantly reduced DUSP6 phosphatase activity (blue circles). 
However, addition of MBP itself did not significantly affect the activity. Phosphatase inhibitor cocktail was added as a positive control to completely 
abolish the activity (red squares). Data are presented as mean ± SEM from 4 independent experiments. *P < 0.05, ANOVA followed by t test. (B) 
Coimmunoprecipitation shows interaction between PLAC8 and DUSP6. HEK293T cells were transfected with the plasmids as labeled. PLAC8 
was coimmunoprecipitated with an anti-Myc antibody from cells expressing Myc-tagged DUSP6, but not from cells expressing only PLAC8.
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We further examined EMT-related markers by immunoblot-
ting (Figure 6C, left panels) and immunofluorescence (Figure 6C, 
right panels). By immunoblotting, levels of CDH1 and CTNND1 
were modestly reduced in HCA-7P8 cells. By immunofluorescence, 
we observed less membranous and increased cytoplasmic CDH1 
expression. By immunoblotting, HCA-7P8 cells exhibited 
increased levels of VIM and ZEB1 compared with parental HCA-7 
cells. VIM immunofluorescence was detected in approximately 
10% of HCA-7P8 cells and, when present, displayed a filamentous 
pattern in the cytoplasm. ZEB1 immunofluorescence was detected 
in nuclei of all HCA-7P8 cells. CDH3 levels were increased in HCA-
7P8 cells and appeared to be more cytosolic compared with CDH3 
in parental HCA-7 cells by immunofluorescence.
Alterations in tight junction proteins have been reported in EMT 
and cancer progression (41–43); thus, we examined the levels and 
localization of a panel of tight junction proteins. Although occlu-
din (OCLN) levels were not significantly altered by PLAC8 over-
expression, the protein relocalized from the plasma membrane 
to cytoplasm (Figure 6D, right panels). Immunoblotting revealed 
elevated levels of tricellulin (TRIC) in HCA-7P8 compared with 
parental HCA-7 cells (Figure 6D, left panels). However, in con-
trast to the typical localization of TRIC at tricellular junctions 
in parental HCA-7 cells, TRIC immunofluorescence was appar-
ent throughout the plasma membrane and in the cytoplasm of 
HCA-7P8 cells (Figure 6D, right panels). By contrast, JAM-A levels 
were reduced and a faster migrating form of ZO-1 was detected in 
lysates from HCA-7P8 cells compared with parental HCA-7 cells. 
For both JAM-A and ZO-1, immunofluorescence was less uniform 
and markedly reduced at the tricellular junctions in HCA-7P8 
cells (Figure 6D, right panels). Taken together, these results show 
that excess PLAC8 results in a number of morphological and bio-
chemical features of EMT. However, in contrast to classical EMT, 
in which CDH2 is transcriptionally upregulated, we observed tran-
scriptional upregulation of CDH3.
PLAC8 enhances ERK2 phosphorylation. To elucidate the molecular 
mechanism by which excess PLAC8 leads to this EMT phenotype, 
we examined signaling pathways linked to EMT, including ERK 
(22, 44), AKT (45, 46), and SRC (ref. 47 and Figure 7A). Phosphory-
lation of ERK2, but not ERK1, has been shown to induce EMT 
(22). Although we observed no difference in total ERK1/2 levels, 
p-ERK1/2 levels were markedly increased in HCA-7P8 cells, with a 
more prominent increase in p-ERK2. There was a modest increase 
in total AKT and p-AKT in HCA-7P8 cells, consistent with previ-
ous findings that PLAC8 increases p-AKT in cultured fibroblasts 
(48). Notably, we observed no difference in total SRC and p-SRC 
between parental HCA-7 and HCA-7P8 cells, further supporting a 
selective contribution of ERK2 in the PLAC8-induced EMT.
To investigate the relative contribution of ERK2 to the HCA-
7P8 EMT phenotype, we knocked down ERK1 or ERK2 using 
lentiviral-based shRNAs (targeting constructs are listed in Sup-
plemental Table 2). Knockdown of ERK2 (shERK2-3), but not 
ERK1 (shERK1-1), caused HCA-7P8 cells to revert from colonies 
with irregular borders and protrusions to smooth-edged colo-
nies (Figure 7, B and C). In contrast to ERK1 knockdown cells, 
ERK2 knockdown cells exhibited increased CDH1 cell surface 
immunofluorescence and markedly decreased CDH3, ZEB1, and 
VIM immunofluorescence (Figure 7D). In addition, administra-
tion of an ERK2-selective inhibitor, pyrazolylpyrrole, reverted 
HCA-7P8 cells from a mesenchymal to an epithelial morphol-
ogy in a concentration-dependent manner and led to a marked 
increase in cell surface CDH1 (Supplemental Figure 7).
PLAC8 directly binds DUSP6 and inhibits its phosphatase activity. To 
investigate the mechanism by which high levels of PLAC8 increase 
ERK2 activation, we examined dual-specificity phosphatases 
(DUSPs) that can dephosphorylate and inactivate ERK1/2. These 
include the nuclear phosphatase DUSP5 (49) and cytosolic phos-
phatases DUSP3 and DUSP6 (23, 50, 51). On the basis of the 
cytosolic localization of PLAC8 in CRC cells, we elected to study 
DUSP6 and DUSP3. To examine the effects of PLAC8 on DUSP6 
and DUSP3 enzymatic activity, we performed in vitro phosphatase 
experiments using recombinant DUSP6 (Figure 8A) and DUSP3 
(Supplemental Figure 8). Since the activity of DUSPs depends 
on binding to ERK2 (52), we added purified ERK2 protein to in 
vitro phosphatase assays. In the presence of purified recombinant 
maltose-binding protein–tagged (MBP-tagged) murine PLAC8, 
DUSP6 phosphatase activity was significantly reduced, as indicat-
Figure 9
Depletion of endogenous PLAC8 in SC cells restores cell surface CDH1 and reduces ERK2 phosphorylation in xenografts. (A) Control SC cells 
(CTL) and SC cells stably expressing PLAC8 shRNAs (sh1 and sh2) were subcutaneously injected into athymic nude mice. After 4 weeks, con-
trol SC cells formed less well-differentiated tumors with minimal CDH1 immunoreactivity (brown) at the membrane (left). In contrast, SC cells 
expressing PLAC8 shRNAs formed glandular tumors with large cysts with CDH1 immunoreactivity (brown) observed at the membrane (middle 
and right). Black box fields are magnified in dashed boxes. Scale bars: 100 μm (top), 20 μm (bottom). (B) Immunoblotting of p-ERK1 (higher band) 
and p-ERK2 (lower band) in xenograft tumors from control SC cells (CTL, left 3 lanes) and from SC cells stably expressing PLAC8 shRNAs (right 
3 lanes). ACTB was used as a loading control.
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ed by decreased hydrolysis (dephosphorylation) of a fluorescence 
substrate, 3-O-methylfluorescein phosphate. As a control, purified 
MBP did not alter DUSP6 phosphatase activity (Figure 8A, green 
circles). Similarly, purified human PLAC8 protein also inhibited 
DUSP6 phosphatase activity (H. Ma and R. Coffey, unpublished 
observations). In contrast, MBP-PLAC8 protein had minimal effect 
on DUSP3 phosphatase activity (Supplemental Figure 8), indicat-
ing selective inhibition of DUSP6 activity by PLAC8.
Next, we tested whether PLAC8 interacts with DUSP6 by coim-
munoprecipitation. Untagged PLAC8 coimmunoprecipitated 
with Myc-tagged DUSP6 when cotransfected into HEK293 cells 
(Figure 8B). In addition, endogenous DUSP6 coimmunoprecipi-
tated with PLAC8 from HCA-7 cells (H. Ma and R. Coffey, unpub-
lished observations). Moreover, yeast 2-hybrid analysis showed 
that PLAC8 and DUSP6 directly interact (Supplemental Table 3 
and Supplemental Figure 9). Taken together, these results indicate 
that PLAC8 overexpression can enhance ERK2 phosphorylation by 
directly binding to DUSP6, and inhibiting its phosphatase activity.
Knockdown of endogenous PLAC8 in SC cells restores cell surface CDH1 
and reduces p-ERK2. Having established the molecular and morpho-
logical effects of selectively overexpressing PLAC8 in HCA-7 cells, 
we returned to the study of HCA-7–derived CC (PLAC8-low) and 
SC (PLAC8-high) cells to test the consequences of knocking down 
PLAC8 in SC cells (Figure 2C). When injected sub-
cutaneously, CDH1 was largely cytoplasmic in 
xenograft tumors from SC cells, but mainly on the 
membrane in CC-derived tumors (Supplemental 
Figure 10A). Stable knockdown of PLAC8 in SC 
cells resulted in restoration of cell surface CDH1 
in xenograft tumors (Figure 9A). Similar results 
were also observed in 3D collagen culture (Supple-
mental Figure 10, B and C). These data support 
the post-transcriptional regulation of CDH1 by 
PLAC8. In addition, p-ERK2 was significantly 
reduced in xenografts from SC cells with PLAC8 
knockdown by immunoblotting (Figure 9B), fur-
ther suggesting that PLAC8 is a critical regulator 
of this unconventional EMT phenotype.
Evidence of EMT in human CRC. To relate the 
above findings to CRC, we used MultiOmyx, a 
novel immunofluorescence-based methodology 
that allows application and analysis of up to 60 
primary antibodies in a single section (53, 54). In 
a representative medullary CRC tumor, PLAC8 
expression was detected throughout the tumor (Figure 10, A and 
E). As expected, expression of the epithelial marker cytokeratin (CK) 
corresponded to the CDH1+ portion of the tumor (Figure 10, F and 
H), and expression of the mesenchymal marker VIM correlated with 
CDH3 expression (Figure 10, G and I). We focused on a region of the 
tumor containing an abrupt transition from CDH1 to CDH3 immu-
noreactivity (Figure 10, A and B color, F and G black and white). 
Notably, our analysis software revealed a CDH3+ region (Figure 10C) 
that contained a large number of cells with cytosolic PLAC8 expres-
sion (Cyt-PLAC8, blue, and Supplemental Figure 11). Examination 
of a subset of these Cyt-PLAC8+ cells (Figure 10D) revealed coexpres-
sion of both CK (false-colored red) and VIM (false-colored green). 
Coexpression of CK, CDH3, VIM, and Cyt-PLAC8 provides in vivo 
evidence that excess PLAC8 may be involved in EMT in human CRC.
Discussion
Previous studies have implicated PLAC8, a small cysteine-rich, 
evolutionarily conserved vertebrate protein (55–57), in multi-
ple types of cancer, including CRC (7, 48, 58, 59). However, the 
molecular functions of PLAC8 in cancer remain to be defined. In 
this study, we show that excess PLAC8 promotes ERK2-depen-
dent unconventional EMT through direct binding to DUSP6 and 
inhibition of its phosphatase activity.
Figure 10
Expression of PLAC8, CDH1, CDH3, CK, and VIM 
in a medullary CRC. (A) Composite view of PLAC8 
(white), CDH1 (red), CDH3 (green), CK (magenta), 
and VIM (blue) expression. (B) Transition from CDH1- 
to CDH3-expressing cells from boxed region in A 
(dotted line). (C) Cells within the CDH3+ (gray) region 
have cytosolic PLAC8 expression (false-colored, 
blue). (D) Expression of CK (false-colored, red), VIM 
(false-colored, green) and cytosolic PLAC8 expres-
sion (false-colored, blue) within the CDH3+ (gray) 
cells. Cells with cytosolic PLAC8 expression and 
coexpression of CK and VIM are boxed and enlarged 
in C and D. (E–I) Single-marker expression of panels 
composited in A. Scale bars in the insets of C and D: 
25 μm; other scale bars: 75 μm.
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sible mechanisms. PLAC8-induced p-ERK2 could activate CK2α 
kinase, which phosphorylates CTNNA1 at S64, resulting in disso-
ciation of the CTNNA1-CTNNB1 complex (68). This would lead to 
destabilization of CDH1 at the membrane and resultant cytoplasmic 
accumulation. It is also possible that PLAC8 overexpression activates 
AKT, which phosphorylates CTNNB1 at S552, disrupting the CDH1-
CTNNB1 interaction (69). In support of PLAC8-induced disruption 
of membranous cadherin-catenin complexes, we observed increased 
cytosolic CTNND1 and CDH1 expression in HCA-7P8 cells (Figure 
6C). PLAC8 knockdown restored cell surface localization of both 
proteins. Knockdown of CBLL1, the E3-ubiquitin ligase for CDH1 
(70), did not affect protein levels or subcellular distribution of CDH1 
(C. Li and R. Coffey, unpublished observations). Furthermore, no 
CDH1 mobility shift was observed by immunoblotting of PLAC8-
overexpressing cell lysates (C. Li and R. Coffey, unpublished observa-
tions). These observations indicate that ubiquitylation by CBLL1 or 
ectodomain cleavage of CDH1 is not mechanistically tied to CDH1 
subcellular localization. Future studies will be needed to determine 
the precise mechanisms by which p-ERK2 regulates CDH1 subcel-
lular localization upon PLAC8 overexpression.
We observed a dynamic pattern of endogenous Plac8.1 distribu-
tion in the course of zebrafish embryogenesis. Plac8.1 was detected 
in largely cytoplasmic puncta at blastula stages, gradually accu-
mulating near cell membranes in mesenchymal cells that become 
more tightly packed and acquire epithelial characteristics during 
the course of gastrulation (31, 32, 71), with expression strongly 
enriched at the apical cell membranes in the developing gut (Fig-
ure 3). This pattern of intracellular Plac8.1 in zebrafish parallels 
our observations for human PLAC8, which was found exclusively 
at the apical domain of fully differentiated normal colonic epithe-
lium (Figure 1, A and B) and moderately differentiated adenocar-
cinomas (Figure 1D). In poorly differentiated carcinomas where it 
was overexpressed, PLAC8 frequently showed cytosolic distribution 
(Figure 1, F and H). It will be instructive to examine the localization 
of PLAC8 protein in adipocytes and dendritic cells given its role in 
brown fat differentiation and immune function (3–5).
We noted that the effects of Plac8 overexpression on cell migra-
tion are different in our 2 model systems. Plac8.1 overexpression in 
zebrafish embryos resulted in decreased mesenchymal cell migra-
tion (Figure 4, D and E); in contrast, PLAC8-overexpressing HCA-7 
cells detached and migrated faster compared with control cells 
(Figure 5B). This difference is likely due to the different modes 
of mesenchymal cell migration in zebrafish embryos and cultured 
human epithelial cells. Mesodermal cells of zebrafish gastrulae 
move as individuals on the surfaces of other cells, and reduced or 
excess Cdh1 impairs cell migration (34, 37, 72–75). In contrast, 
cancer cells can invade and migrate as individual cells after detach-
ing from epithelia, which is facilitated by loss of membrane adhe-
sion molecules, including CDH1 (76).
Our work also introduces a new 3D system for studying CRC. Pio-
neering work by the laboratories of Mina Bissell and Joan Brugge 
has shown the biological relevance of studying breast cancer cells in 
3D rather than on plastic (77, 78). Such 3D model systems for CRC 
are limited and have relied largely on Caco-2 cells (79). Similar to 
Caco-2 cells, HCA-7 cells form a uniform polarizing monolayer when 
cultured on Transwell filters (80). HCA-7–derived CC and SC cells 
display 2 distinct morphologies and behaviors when cultured in type 
I collagen. We believe this will be a useful and highly tractable in vitro 
model system to study colon cancer cell behavior and to identify mol-
ecules, like PLAC8, that contribute to tumor progression.
We provide the first description of endogenous PLAC8 protein 
distribution, showing that both human PLAC8 and zebrafish 
Plac8.1 localize to the apical domain of normal differentiated gut 
epithelium. Future studies will address the regulation of PLAC8 
subcellular localization and its function at the apical domain and 
in the cytoplasm. It is interesting to note that cytosolic PLAC8 
is a feature of tumors with microsatellite instability (MSI) and 
MSI CRC–derived cell lines, which are characterized by frequent 
somatic mutations (60). Both mucinous and medullary CRCs tend 
to be MSI, and KM12C, LoVo, and HCA-7 cell lines were derived 
from MSI CRCs. It will be important to determine whether excess 
PLAC8 is a common feature of MSI CRCs and whether cytosolic 
PLAC8 correlates with increased p-ERK2 in this subset of CRCs. If 
so, we hypothesize that PLAC8 is normally tethered at the subapi-
cal plasma membrane by proteins that become mutated in can-
cer; in this setting, PLAC8 is released into the cytoplasm, where it 
takes on its neomorphic function to bind and inactivate DUSP6, 
increasing p-ERK2 and leading to an EMT-like phenotype.
Considerable evidence supports an important role for EMT in 
cancer progression (8, 9). Classic EMT is a transcriptional pro-
gram in which CDH1 expression is suppressed, while CDH2 and 
mesenchymal genes, such as VIM, are induced. Here, we describe an 
unconventional EMT that occurs in the presence of excess, mislocal-
ized PLAC8. This EMT is characterized by a cadherin switch, where 
cell surface CDH1 is reduced in a post-transcriptional manner and 
CDH3 is transcriptionally upregulated; there is no change in CDH2 
expression. The characterization of the complex cellular phenotype 
of cells undergoing EMT was demonstrated using MultiOmyx tech-
nology, whereby colocalization of the 5 proteins of interest (PLAC8, 
VIM, CK, CDH1, and CDH3) was determined at a single-cell level in 
situ. Visualizing the patterns of expression for these 5 proteins with 
the color-coding method reveals the dynamic nature of this process 
at the invasive front of a medullary CRC. Overexpression of CDH3 
has been implicated in CRC progression, although upregulation of 
CDH3 is not a classical feature of EMT. Expression of CDH3 (61, 
62) in cancer cells promotes cell motility, migration, and invasion, 
potentially by interfering with CTNND1 binding to CDH1 (63) or 
promoting cytoplasmic accumulation of CTNND1 (64). CDH3 
binding CTNND1 through the juxtamembrane domain may be 
crucial for induction of invasion (65, 66) by preventing CDH1 from 
binding to and stabilizing CTNND1 (67).
We identified enhanced p-ERK2 as a mediator of many of 
the EMT-related effects of excess PLAC8. Previous studies have 
linked p-ERK2 to EMT through transcriptional upregulation of 
ZEB1, ZEB2, and FRA1 (22). In our system, PLAC8 overexpres-
sion did not affect FRA1 levels (Y. Wang and R. Coffey, unpub-
lished observations). We show that knockdown of ERK2 (but not 
ERK1) in HCA-7P8 cells restored cell surface CDH1, indicating 
that CDH1 relocalization away from the membrane is down-
stream of ERK2 phosphorylation. Similar results were also seen 
using a selective ERK2 inhibitor (Supplemental Figure 7), further 
supporting that ERK2 phosphorylation regulates subcellular 
localization of CDH1. Mechanistically, we found PLAC8 directly 
interacts with DUSP6 and inhibits its phosphatase activity. We 
also identified increased p-ERK in zebrafish embryos overex-
pressing Plac8.1 (Supplemental Figure 12), further linking the 
studies in zebrafish and CRC cells.
The precise mechanism(s) through which active ERK2 reduces cell 
surface CDH1 remains to be elucidated. We hypothesize that p-ERK2 
could destabilize the CDH1-catenin complex through multiple pos-
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Magnetically attachable stencil invasion assay. The assay was performed as 
previously described (39). Briefly, a magnetically attachable stencil was 
placed onto 12-well dishes, previously coated with monomeric collagen 
(0.1 mg/ml collagen I). HCA-7C and HCA-7P8 cells were seeded at high 
density. After 48 hours, the stencil was removed and cell movement was 
monitored by time-lapse microscopy.
TMA construction and TMA slide preparation. The TMA was constructed 
on a manual Beecher arrayer and consisted of 1-mm cores in triplicates 
from paraffin blocks of primary CRCs from 84 patients. A variety of CRC 
subtypes (mucinous, medullary, and signet ring cell carcinomas) from all 
4 cancer stages were included. Ten cores of normal colonic mucosa were 
included as controls. Freshly cut 5-μm paraffin sections were used for 
immunohistochemistry.
Mouse xenografts. For SC and CC cells, 4 × 106 cells of each cell line in 100 μl 
PBS suspensions were injected subcutaneously in both flanks. Tumors 
were harvested 56 days after injection. The harvested tumors were fixed 
in 10% formalin for paraffin embedding or snap-frozen. For KM12SM 
pLKO.1 shRNA vector control, KM12SM pLKO.1-PLAC8-929 shRNA cells, 
LoVo pLKO.1 shRNA vector control, and LoVo pLKO.1-PLAC8-929 shRNA 
cells, 2 × 106 cells of each cell line in 100 μl serum-free DMEM were injected 
subcutaneously in 1 flank of each nude mouse. The lengths and widths of 
tumors were measured twice weekly with an external caliper. Tumor vol-
umes were calculated using the modified ellipsoid formula, volume = 1/2 
(length × width2) (83, 84).
Identification and cloning of zebrafish plac8 homologs. Zebrafish plac8 
homologs were identified using TLBSTN algorithm (Basic Local Align-
ment Search Tool, http://blast.ncbi.nlm.nih.gov/) with human PLAC8 
(AAH12205.1) and mouse Plac8 (NP_631937.1) protein sequences. Can-
didate genes were further screened and validated by syntenic analysis. 
Two previously uncharacterized genes from the zebrafish gene collection 
(ZGC), Zgc114201 and Zgc158845, were renamed as plac8.1 and plac8.2, 
respectively. The expression constructs pCS2-Plac8.1, pCS2-Plac8.1-EGFP, 
or pCS2-Plac8.1-mCherry and pCS2-Plac8.1-mt3-EGFP were subcloned 
from plac8.1 cDNA (Open Biosystems).
Zebrafish embryo injection. Sense-capped RNA was synthesized by the 
mMESSAGE mMACHINE RNA synthesis kit (Ambion) from enzyme-
treated and linearized plasmid templates. The synthesized RNA was puri-
fied and examined with both spectrometry and agarose gel electropho-
resis to ensure expected molecular weight and integrity before injection. 
Embryos were injected at the 1-cell stage, unless mosaic injection is noted. 
For mosaic injection, single cells of 32-cell-stage embryos were injected.
Whole-mount ISH of zebrafish. The full-length coding sequence of plac8.1 
was used to generate digoxigenin-labeled sense and antisense RNA probes. 
The digoxigenin-labeled probe used to detect ntl expression was from pub-
lished studies (33). The labeled probes were examined with spectrometry 
and agarose gel electrophoresis to ensure integrity and expected molecular 
weight. For whole-mount ISH, zebrafish embryos of desired stages were 
fixed in 4% PFA. The subsequent steps for whole-mount ISH were per-
formed as previously described (85). Micrographs of whole-mount embry-
os were collected with a Discovery V12 stereomicroscope with an AxioCam 
MRc camera and AxioVision software (Carl Zeiss MicroImaging).
Time-lapse imaging and analysis. Multi-Z-plane differential interference 
contrast (DIC) time-lapse images were collected with a Quorum WaveFX-
X1 spinning disc confocal system (Quorum Technologies) equipped with 
MetaMorph software (Molecular Devices). Zebrafish embryos were dechlo-
rinated in 0.3× Danieau at 60% epiboly (about 7 hours post-fertilization 
[hpf]). Embryos were then mounted in glass-bottom dishes (MatTek) with 
0.75% low-melt agarose (Lonza), with the lateral mesoderm close to the 
glass for time-lapse imaging with a ×10 objective (86). Mesodermal cells 
were imaged from 70% epiboly (7.5 hpf) to 75% epiboly (8 hpf) at 0.5-min-
Methods
Plasmids, transfection, and infection of human cell lines. Expression vectors for 
human PLAC8 (pcDNA3.1-PLAC8, pcDNA3.1-PLAC8-FLAG, pRetroX-
Tight-Pur-PLAC8, and pcDNA3.1-PLAC8-EGFP) were cloned from full-
length cDNA (OriGene). For knockdown experiments, shRNA lentivirus 
(Supplemental Table 2) was packaged in HEK293 cells that were cotrans-
fected with pCMV-dR8.2 dvpr and pMD2.G plasmids (81). Lentivirus-con-
taining media were filtered through 0.45-μm cellulose acetate syringe filters 
(VWR Scientific) before infection. Lentivirus-infected cells were cultured in 
DMEM (Corning cellgro) supplemented with 0.5 μg/ml puromycin.
Antibody generation, immunofluorescence, and immunohistochemistry. Anti–
human PLAC8 and anti–zebrafish Plac8.1 antibodies were generated by 
immunization of rabbits with KLH-conjugated peptides of amino acid 
sequences from the C-terminus of human PLAC8 (CQIKRDINRRRAMRTF) 
or zebrafish Plac8.1 (CQLKRDIDIRKSNGTLKL), respectively (Covance Inc.). 
Specificity of both anti-PLAC8 and anti-Plac8.1 antibodies was validated 
using FLAG-tagged and untagged peptides. Additional validation was per-
formed by shRNA or morpholino knockdown in mammalian cells and zebra-
fish, respectively (Supplemental Figure 2). For CDH1 immunofluorescence, 
cells were fixed in HistoChoice Tissue Fixative (Sigma-Aldrich, H2904) for 15 
minutes. Cells for all other immunofluorescence assays were fixed in 4% PFA, 
then permeabilized with 0.5% Triton X-100 for 10 minutes, stained with 
appropriate antibodies, and followed by confocal microscopic analysis. 
Whole-mount immunofluorescence of zebrafish embryos was performed 
as previously described (82). For immunohistochemistry, tissue sections 
were deparaffinized and antigen retrieval was performed using Target 
Antigen Retrieval Solution (Dako, S1699) for 20 minutes. Sections were 
then incubated with primary antibodies (Supplemental Table 4) overnight 
at room temperature. Secondary antibodies used for immunofluorescence 
and immunohistochemistry include HRP- or Cy3-conjugated donkey 
anti-mouse or anti-rabbit IgGs (Jackson ImmunoResearch), and Alexa 
488– or Alexa 568–conjugated goat anti-mouse or anti-rabbit IgGs (Life 
Technologies). All other chemicals were purchased from Sigma-Aldrich 
unless otherwise stated.
Immunoblotting. Cells were lysed in either cell lysis buffer (25 mM Tris 
HCl, 150 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM 
DTT, and 2% BSA) or M-PER (Pierce) with protease inhibitor cocktail 
(Sigma-Aldrich, P2714). For PLAC8 immunoblotting, tissues or cultured 
cells were lysed in 8 M urea SDS sample buffer (2% SDS, 0.125 M Tris-HCl 
[pH 6.8], 8 M urea, 10% BME). Zebrafish embryos were manually dechori-
onated and homogenized in NP-40 lysis buffer (1% Nonidet P-40, 50 mM 
Tris-HCl [pH 7.4], 150 mM NaCl, 2 mM EDTA, 50 mM NaF, and 10% glyc-
erol). See complete unedited blots in the supplemental material.
2D and 3D cell culture. HCA-7, SW480, SW620, KM12C, KM12SM, and 
LoVo cells and all their derivatives were grown in DMEM supplemented 
with 10% bovine growth serum, glutamine, nonessential amino acids, 100 
U/ml penicillin, and 100 μg/ml streptomycin (HyClone) at 37°C and 5% 
CO2. For soft agar culture, cells were grown on plastic for 4 days before 
being plated in 6-well dishes in triplicate at 0.5 × 104 cells/ml in 0.4% type 
VII agarose (Sigma-Aldrich) over a hardened layer of 0.8% agarose. Col-
onies were counted (Oxford Optronix GelCount) after 13–25 days. 3D 
collagen cultures were set up using 3 layers of type I collagen (PureCol, 
Advanced BioMatrix) in 12-well dishes in triplicates. Top and bottom lay-
ers consisted of 400 μl per well of collagen diluted to 2 mg/ml in medium. 
The middle layers consisted of 400 μl per well of 2 mg/ml collagen in 
medium and contained 5,000 cells/ml. One milliliter medium was added 
on top of each collagen sandwich. Medium was changed every 2–3 days. 
Colonies were counted (Oxford Optronix GelCount) after 14–18 days. 
Colonies were either fixed in 4% PFA for immunofluorescence or lysed for 
immunoblotting post-counting.
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(Clontech) was transformed with 1 μg DNA using the lithium acetate 
method (87). After transformation, yeast cells were streaked on selection 
SD-LW (lacking leucine and tryptophan), SD-HLW (lacking histidine, leu-
cine, and tryptophan), and SD-AHLW (lacking alanine, histidine, leucine, 
and tryptophan) agar plates and incubated for 3 days at 30°C.
In vitro phosphatase activity assay. Recombinant full-length DUSP6 and 
DUSP3 proteins were purchased from Creative BioMart. Phosphatase 
activity was measured using 0.1 mg/ml 3-O-methylfluorescein phosphate 
as the substrate in a 96-well plate assay with a BioTek Synergy 4 plate 
reader (excitation 485 nm, emission 528 nm) (88, 89). The phosphatase 
buffer contained 50 mM Tris-HCl (pH 8.2), 100 mM NaCl, 1 mM DTT, 
and 10% glycerol. For DUSP3 phosphatase activity assay, a final concen-
tration of 0.22 μM DUSP3 was mixed with 1.2 μM of MBP-PLAC8 or MBP 
protein in a final volume of 100 μl in phosphatase assay buffer. PhosSTOP 
phosphatase inhibitor cocktail tablets (Roche) were used as a control (1 
tablet was dissolved in 7 ml PBS buffer, and 5 μl was used). For DUSP6 
phosphatase activity assay, a final concentration of 0.25 μM DUSP6 was 
mixed with 0.625 μM ERK2 protein and 1.2 μM of MBP-PLAC8 or MBP 
protein in a final volume of 100 μl in phosphatase assay buffer.
Statistics. ANOVA, 2-tailed Student’s t test, and Mann-Whitney U test 
were used to determine statistical significance. P values less than 0.05 were 
considered significant. Calculations were performed using GraphPad for 
Mac, Matlab 2010 for Mac, and R 2.15 (64-bit for Mac).
Study approval. All human samples used in this study were considered 
surgical waste and exempt from IRB approval. All protocols and experi-
ments performed in mice were approved by the Vanderbilt University Med-
ical School (Nashville, TN). All protocols and experiments performed in 
zebrafish were approved by the Washington University School of Medicine 
(St. Louis, MO) and Vanderbilt University Medical School (Nashville, TN).
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ute intervals for 30 minutes with 2 μm Z increments using a ×40 water-
immersion objective. The collected time-lapse images were processed using 
MetaMorph software. Cell morphometric analysis and cell movement 
tracking were performed manually using ImageJ. Statistical analysis and 
data plotting were performed with Prism software (GraphPad Software 
Inc.). The angle data were plotted with Rose.Net software (http://mypage.
iu.edu/~tthomps/programs/).
RNA isolation, qRT-PCR, and qPCR array analysis. Total RNA from human 
cells or zebrafish embryos was extracted with TRIzol Reagent (Invitrogen), 
digested with DNase, and further purified using the RNeasy Mini Kit (Qia-
gen). cDNA was generated with SuperScript II reverse transcriptase (Life 
Technologies). qRT-PCR was performed in triplicate using the StepOneP-
lus Real-Time PCR System (Applied Biosystems) in 3 independent experi-
ments. Each 20-μl reaction contained 0.1 μM primers (for sequence infor-
mation see Supplemental Table 5A), 4 mM MgCl2, and EXPRESS SYBR 
GreenER Supermix with Premixed ROX (Life Technologies, A10315) and 
was run under the following conditions: 95°C 2 minutes, 95°C 15 sec-
onds, 58°C 45 seconds for 45 cycles followed by melting curve validation. 
Human EMT RT2 Profiler PCR Array (Qiagen, PAHS-090Z) was used for 
screening by qRT-PCR according to the manufacturer’s instructions.
Genotyping. The cdh1vu44 and wild-type cdh1 alleles were distinguished by 
a PCR-generated restriction fragment length polymorphism method. PCR 
products from VU44 primers (Supplemental Table 5B) were digested with 
DdeI and resolved by agarose gel electrophoresis. The cdh1vu44 allele pro-
duced products of 104 bp and 216 bp, whereas the wild-type cdh1 allele 
produced a single product of 310 bp.
ERK2 inhibitor treatments. HCA-7P8 cells plated on coverslips were treated 
with ERK2-selective inhibitor, pyrazolylpyrrole, at a concentration of 10 or 
100 nM from day 1 for 5 days. Cells were fixed in HistoChoice fixative for 
15 minutes and then permeabilized using 0.5% Triton X-100 PBS for 10 
minutes, followed by DIC microscopy or immunofluorescence.
Serial multiplexed immunofluorescence microscopy (MultiOmyx). The Mul-
tiOmyx platform allows a standard FFPE tissue section to be processed 
and stained repetitively with Cy3-, Cy5-, and Cy7-conjugated antibodies 
separately or simultaneously as recently described (refs. 53, 54, and see 
Supplemental Table 6 for specific antibody-dye combinations and stain-
ing sequence). Image capture was performed, as previously described (54), 
using an automated epifluorescent Olympus IX-81 microscope outfitted 
with software developed at GE Global Research for reimaging of same 
fields of view. Image stacks were then registered, using DAPI stains col-
lected at each round of imaging, and autofluorescence was removed as 
previously described (53, 54). Composite image overlays were generated by 
the importing of grayscale TIFF images into .ZVI format (AxioVision 4.6, 
Carl Zeiss Microscopy) and unique pseudocolors assigned to the respective 
images. Images were analyzed and false-colored using visualization soft-
ware as previously described (54). The threshold for cytoplasmic PLAC8 
expression was set to 10% of the cell population using software as previ-
ously described (54). The threshold of the other markers was set to include 
all positively expressing cells. Images for PLAC8+ cells were then overlaid 
with cells coexpressing VIM and CK or CDH1 and CDH3.
Immunoprecipitation. HEK293 cells were transfected with Lipofectamine 
2000 (Life Technologies). Cells were lysed in NP-40 lysis buffer 24 hours 
after transfection. Soluble lysates were precleared with protein G Sepha-
rose Beads (Life Technologies), then 2.5 μg anti-Myc (9E10) antibody or 
anti-GFP antibody (Life Technologies, A-11122) was added. After over-
night incubation at 4°C, Dynabeads Protein G (Life Technologies) were 
used to precipitate immunocomplex for immunoblotting analysis.
Yeast 2-hybrid. The full-length cDNA of PLAC8 was cloned to pGADT7, 
and the full-length cDNA of DUSP6 was cloned into pGBKT7 vector of 
Matchmaker yeast 2-hybrid system (Clontech). The yeast strain AH109 
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